Disease hub
Glioblastoma
Open Targets catalogue label: glioblastoma
This hub aggregates source-backed disease–target and disease–drug rows, registry trial mirrors, and deterministic CANTI research signals that mention linked drugs — for clinician discussion only. It does not summarize standard-of-care pathways or individualized care plans; every surface requires oncology review.
Also indexed as: GBM · glioblastoma multiforme · WHO grade IV · grade IV astrocytoma · glioblastoma · MONDO_0018177
Data: Live structured evidence (Supabase)
Loaded rows last touched 2026-05-16 (UTC) — connector schedules run server-side; api_sync_log is not on the public read surface.
View glioblastoma guided lookup
Limitations & build flags
- Read-only structured navigator
- No clinical outcome benefit inferred
- Trial presence does not imply success
- Drug identity may require normalization
- Terminated/withdrawn trials must remain visible
Current CANTI coverage
0% indexed vs source total
0 of 7,333 — CANTI prefers formal indexed rows when the probe captured them, otherwise hub-visible rows, versus the Open Targets associated-target total.
Indexed can read as zero while hub-visible symbols are higher when drug–target links surface markers that are not yet written as formal disease–target evidence rows — both are database views, not clinical findings.
- Source total associated targets
- 7,333
- Indexed in CANTI (live)
- 498
- Shown on this page (live)
- 500
- Last checked
- 2026-05-14 21:35:46 UTC
From Open Targets GraphQL count (last probe).
Distinct symbols in disease_target_evidence bucketed to this hub. Snapshot at probe: 0.
Unique linked targets on this hub (includes drug–target links). Snapshot at probe: 5.
Coverage mode: top_25
Fetched row scores (probe window): min 0.11505994378809836, median 0.16857345190391865, max 0.3443362470873648.
Open Targets universe (Phase 8M.0)
Open Targets lists 7,333 associated targets for this disease node in the Platform — a catalogue-size signal, not treatment guidance.
- Associated targets (source)
- 7,333
- Count type
- Exact (GraphQL count)
- Indexed / shown vs universe
- 498 indexed live · 500 shown live — 6.8% of source total
- Last checked
- 2026-05-15 14:18:35 UTC
CANTI has only indexed a subset of the Open Targets association catalogue for this hub. Higher Platform counts do not imply missing clinical care signals.
Empty groups on this hub mean no matching indexed rows in CANTI yet, not “no biological evidence.” Preload sizing: see docs/runbooks/gbm-preload.md.
Choose a preset depth for the public queue. Wider “full catalog” style runs stay operator-led so public traffic cannot trigger unbounded work.
Full review breadth
Operator approval only — not available as a public button. Use your internal change process if the hub needs a larger, cost-reviewed materialization pass.
EFO_0000519. Association score ranks disease–target evidence (higher = stronger catalogue association). Tiers A–D summarize score/evidence bands. Requires oncology review — not a care plan.Targets
Showing 0 of 0Drugs (ranked GBM disease–drug)
Showing 0 of 0Mechanism of action
| Drug | Target | Mechanism | Action | Class | Source |
|---|---|---|---|---|---|
| Select a target, drug, or MoA facet to load mechanism links. | |||||
Trials
NCT IDs derived from disease–drug source URLs; titles/status enriched from clinical_trials when present.
| Study | Title | Drug | Phase | Status | Link |
|---|---|---|---|---|---|
| Select a target or drug to load linked trial summaries. | |||||
Graph-derived rankings
Compact server aggregates over active edges. Counts are graph connectivity — not efficacy or clinical priority.
Shared-target drugs
Graph-derived · not a biological claim
Multi-target drugs
Graph-derived · not a biological claim
Targets with most linked drugs
Graph-derived · not a biological claim
Drugs with most trials
Graph-derived · not a biological claim
Open trial status does not mean eligibility or suitability. Review with oncology team.
Requires oncology review — empty groups mean no matching rows in this load window, not a claim about biology or clinical use. Large lists load progressively.
- ClinicalTrials.govLive when indexed
Registry mirror rows in clinical_trials when operators run the CT.gov enrichment CLI — browser never calls the registry directly.
- Open TargetsLive when indexed
Disease–target evidence rows when operators run enrich:opentargets (GraphQL from trusted scripts only).
- ChEMBLLive when indexed
Drug–target and related enrichment rows when operators run enrich:chembl (server/CLI only).
- CANTI signal builderLive when indexed
Deterministic repurposing-signal rows produced by the in-repo signal builder when operators run the build pipeline.
Rows from disease_target_evidence bucketed to this hub (499 total).
Distinct symbols from disease rows and drug_targets on linked drugs (500 total).
ABCC3
ATP-binding cassette sub-family C member 3
ABCC4
ATP-binding cassette sub-family C member 4
ABCG1
—
ACSBG1
—
ADAM15
—
ADAR
—
ADARB1
—
ADARB2
—
ADGRE2
—
AGTR2
—
AHR
—
AKIRIN2
—
Drug records referenced by disease–drug or disease–target rows (94 total).
AGLATIMAGENE BESADENOVEC
aglatimagene besadenovec
MEFLOQUINE
mefloquine
CARBOXYAMIDOTRIAZOLE
carboxyamidotriazole
OLARATUMAB
olaratumab
ACETYLCYSTEINE
acetylcysteine
ERLOTINIB HYDROCHLORIDE
erlotinib hydrochloride
ONARTUZUMAB
onartuzumab
AVADOMIDE
avadomide
IRINOTECAN HYDROCHLORIDE
irinotecan hydrochloride
SODIUM CHLORIDE
sodium chloride
FLUCICLOVINE F18
fluciclovine f18
LUCANTHONE
lucanthone
disease_drug_evidence rows whose evidence_type suggests approved-elsewhere discussion context — discussion only.
No matching rows
Import repoDB-compatible disease–drug evidence or add structured rows to surface discussion candidates here.
Registry mirror rows matched to this hub (253 total).
NCT01721577 — Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas
Status: TERMINATED · Stopped or withdrawn trials · clinicaltrials.gov
These rows can provide caution or historical context.
Open trials hubNCT00365222 — Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma
Status: TERMINATED · Stopped or withdrawn trials · clinicaltrials.gov
These rows can provide caution or historical context.
Open trials hubNCT02669173 — Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Status: COMPLETED · Completed trials with indexed results · clinicaltrials.gov
Open trials hubNCT05053880 — A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
Status: UNKNOWN · Other historical trials · clinicaltrials.gov
Open trials hubNCT07411690 — Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial Tumors
Status: RECRUITING · Open or active trials · clinicaltrials.gov
Open trials hubNCT01808820 — Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma
Status: COMPLETED · Other historical trials · clinicaltrials.gov
Open trials hubNCT00979862 — Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
Status: COMPLETED · Other historical trials · clinicaltrials.gov
Open trials hubNCT00761280 — Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
Status: TERMINATED · Stopped or withdrawn trials · clinicaltrials.gov
These rows can provide caution or historical context.
Open trials hubNCT02864368 — Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
Status: TERMINATED · Stopped or withdrawn trials · clinicaltrials.gov
These rows can provide caution or historical context.
Open trials hubNCT01700569 — Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma
Status: TERMINATED · Stopped or withdrawn trials · clinicaltrials.gov
These rows can provide caution or historical context.
Open trials hubNCT05775458 — Glutamate Excitotoxicity and Its Role in Glioblastoma Biology
Status: RECRUITING · Open or active trials · clinicaltrials.gov
Open trials hubNCT05686798 — Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
Status: RECRUITING · Open or active trials · clinicaltrials.gov
Open trials hubdrug_repurposing_signals rows with source containing "canti" (28 total).
Repurposing research signal · AGLATIMAGENE BESADENOVEC · v0.1
Deterministic research signal for AGLATIMAGENE BESADENOVEC. Aggregate template score 25 (not a clinical endpoint). Contributing canonical sources observed in this rollup: clinicaltrials.gov. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: Open Targets disease–target evidence; ChEMBL mechanism-backed drug–target edges; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · CARBOXYAMIDOTRIAZOLE · v0.1
Deterministic research signal for CARBOXYAMIDOTRIAZOLE. Aggregate template score 25 (not a clinical endpoint). Contributing canonical sources observed in this rollup: clinicaltrials.gov. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: Open Targets disease–target evidence; ChEMBL mechanism-backed drug–target edges; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · ACETYLCYSTEINE · v0.1
Deterministic research signal for ACETYLCYSTEINE. Aggregate template score 40 (not a clinical endpoint). Contributing canonical sources observed in this rollup: clinicaltrials.gov, repodb. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: Open Targets disease–target evidence; ChEMBL mechanism-backed drug–target edges. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · AVADOMIDE · v0.1
Deterministic research signal for AVADOMIDE. Aggregate template score 25 (not a clinical endpoint). Contributing canonical sources observed in this rollup: clinicaltrials.gov. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: Open Targets disease–target evidence; ChEMBL mechanism-backed drug–target edges; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · BERUBICIN HYDROCHLORIDE · v0.1
Deterministic research signal for BERUBICIN HYDROCHLORIDE. Aggregate template score 25 (not a clinical endpoint). Contributing canonical sources observed in this rollup: clinicaltrials.gov. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: Open Targets disease–target evidence; ChEMBL mechanism-backed drug–target edges; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · ATEZOLIZUMAB · v0.1
Deterministic research signal for ATEZOLIZUMAB. Aggregate template score 25 (not a clinical endpoint). Contributing canonical sources observed in this rollup: clinicaltrials.gov. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: Open Targets disease–target evidence; ChEMBL mechanism-backed drug–target edges; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · BASILIXIMAB · v0.1
Deterministic research signal for BASILIXIMAB. Aggregate template score 25 (not a clinical endpoint). Contributing canonical sources observed in this rollup: clinicaltrials.gov. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: Open Targets disease–target evidence; ChEMBL mechanism-backed drug–target edges; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · AMINOLEVULINIC ACID HYDROCHLORIDE · v0.1
Deterministic research signal for AMINOLEVULINIC ACID HYDROCHLORIDE. Aggregate template score 25 (not a clinical endpoint). Contributing canonical sources observed in this rollup: clinicaltrials.gov. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: Open Targets disease–target evidence; ChEMBL mechanism-backed drug–target edges; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · ASCORBIC ACID · v0.1
Deterministic research signal for ASCORBIC ACID. Aggregate template score 40 (not a clinical endpoint). Contributing canonical sources observed in this rollup: clinicaltrials.gov, repodb. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: Open Targets disease–target evidence; ChEMBL mechanism-backed drug–target edges. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · AZD-1390 · v0.1
Deterministic research signal for AZD-1390. Aggregate template score 25 (not a clinical endpoint). Contributing canonical sources observed in this rollup: clinicaltrials.gov. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: Open Targets disease–target evidence; ChEMBL mechanism-backed drug–target edges; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · CEDIRANIB MALEATE · v0.1
Deterministic research signal for CEDIRANIB MALEATE. Aggregate template score 25 (not a clinical endpoint). Contributing canonical sources observed in this rollup: clinicaltrials.gov. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: Open Targets disease–target evidence; ChEMBL mechanism-backed drug–target edges; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · ACT-001 · v0.1
Deterministic research signal for ACT-001. Aggregate template score 25 (not a clinical endpoint). Contributing canonical sources observed in this rollup: clinicaltrials.gov. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: Open Targets disease–target evidence; ChEMBL mechanism-backed drug–target edges; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubStructured rows with negative evidence_direction (0 total).
No negative-direction rows
When structured evidence includes explicit negative direction fields, they surface here for oncology review.
- opentargets: 499
- clinicaltrials.gov: 492
- canti_signal_builder: 28
- chembl: 3
- repodb: 1